Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT03709706
Title Pilot Immunotherapy Study With Autologous T-cells Specific for NY-ESO-1/ LAGE-1a-positive Advanced NSCLC Either Alone or in Combination With Pembrolizumab
Recruitment Recruiting
Gender both
Phase Phase Ib/II
Variant Requirements Yes
Sponsors GlaxoSmithKline

lung non-small cell carcinoma


NY-ESO-1-c259T + Pembrolizumab


Age Groups: adult | senior
Covered Countries USA | CAN

Additional content available in CKB BOOST